Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Community Focus

Explore the latest updates and expert interviews

The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Latest Videos Videos by Disease Videos by Congress Features Podcasts

Welcome to the Community Focus Channel

Intended for community physicians, this channel aims to inform clinical practice through expert interviews from major international congresses.

The diagnosis, treatment and management of patients with hematological conditions and malignancies is rapidly evolving, and with an influx of therapeutic options, physicians may find it difficult to decide which management strategy is best for their patients. Although cutting-edge research is at the heart of clinical development, data from trials are not always directly applicable to clinical practice or easily digested. The Community Focus Channel aims to empower community physicians by providing the knowledge and resources to support evidence-based practice and improve patient outcomes.

Multiple Myeloma

View all
2:49
Reveal-MM: retrospective evaluation of healthcare patterns in the years preceding myeloma diagnosis
Faith Davies • 7 Dec 2025
2:25
Combined assessment of CTCs and MRD for dynamic risk assessment of patients with multiple myeloma
Bruno Paiva • 6 Dec 2025

Lymphoma

View all
1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
1:37
Improving CAR T-cell therapy referral patterns of patients with R/R LBCL in the US
Tara Graff • 8 Dec 2025

CLL

View all
1:15
Treatment options for patients with CLL who have developed resistance to covalent BTK inhibitors
Paolo Ghia • 8 Dec 2025
9:23
CLL17 trial: fixed-duration vs continuous targeted treatment for previously untreated CLL
Othman Al-Sawaf • 6 Dec 2025

MPNs

View all
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa • 6 Dec 2025
3:32
The management of patients with ET or PV during pregnancy
Mary Frances McMullin • 7 Dec 2025

AML

View all
8:00
HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML
Jesse Tettero • 6 Dec 2025
2:46
The dosing and duration of venetoclax treatment for AML: balancing efficacy with tolerability
Pinkal Desai • 7 Dec 2025

Non-Malignant

View all
6:21
Key barriers to equitable hematologic care in India and priorities for the next decade
Rohan Halder • 25 Nov 2025
4:49
Acute chest syndrome in sickle cell disease: pathophysiology, management, and prevention
Subarna Chakravorty • 3 Nov 2025

Videos by Disease

Multiple Myeloma
Lymphoma
Leukemia
MDS
MPNs
Non-Malignant
2:49
Reveal-MM: retrospective evaluation of healthcare patterns in the years preceding myeloma diagnosis
Faith Davies • 7 Dec 2025
2:25
Combined assessment of CTCs and MRD for dynamic risk assessment of patients with multiple myeloma
Bruno Paiva • 6 Dec 2025
3:08
Isa-VRd in older patients with/without frailty criteria: pooled analysis in newly diagnosed myeloma
Enrique Ocio • 6 Dec 2025
1:58
Sequencing bispecific antibodies and CAR-T in multiple myeloma
Rakesh Popat • 5 Dec 2025
View All Videos
1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
1:37
Improving CAR T-cell therapy referral patterns of patients with R/R LBCL in the US
Tara Graff • 8 Dec 2025
1:15
Quality improvement initiative to optimize AE management for bispecifics for DLBCL in the community
Krish Patel • 8 Dec 2025
3:21
Combined chemotherapy and consolidative radiation versus chemotherapy alone in early-stage cHL
Jakub Svoboda • 7 Dec 2025
View All Videos
1:15
Treatment options for patients with CLL who have developed resistance to covalent BTK inhibitors
Paolo Ghia • 8 Dec 2025
8:00
HARMONY Alliance study: validation of MRD as a surrogate endpoint in AML
Jesse Tettero • 6 Dec 2025
9:23
CLL17 trial: fixed-duration vs continuous targeted treatment for previously untreated CLL
Othman Al-Sawaf • 6 Dec 2025
1:28
Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL
Tara Graff • 8 Dec 2025
View All Videos
1:07
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
Jennifer Marvin-Peek • 6 Dec 2025
11:48
Ask the Expert: Naval Daver answers your AML questions at iwAL 2025
Naval Daver • 21 Sep 2025
7:55
Lower-risk MDS: improving outcomes with luspatercept, imetelstat & new agents
Valeria Santini • 5 Sep 2025
1:43
The significance of anemia in MDS & MPNs and the need to develop effective therapies
Matteo Della Porta • 5 Sep 2025
View All Videos
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa • 6 Dec 2025
3:32
The management of patients with ET or PV during pregnancy
Mary Frances McMullin • 7 Dec 2025
1:54
Therapeutic options available in the UK for patients with myelofibrosis
Mary Frances McMullin • 7 Dec 2025
1:27
Preventing or reversing transfusion dependence to improve outcomes in myelofibrosis
Haifa Kathrin Al-Ali • 6 Dec 2025
View All Videos
6:21
Key barriers to equitable hematologic care in India and priorities for the next decade
Rohan Halder • 25 Nov 2025
4:49
Acute chest syndrome in sickle cell disease: pathophysiology, management, and prevention
Subarna Chakravorty • 3 Nov 2025
10:55
Transplantation and gene therapy in SCD and thalassemia: donor types and indications
Subarna Chakravorty • 3 Nov 2025
1:52
Managing sickle cell disease in pregnancy: utilizing prophylactic transfusions in this setting
Sheinei Alan • 16 Oct 2025
View All Videos

Videos by congress

IMS 2025
iwCLL 2025
SOHO 2025
MPN Workshop of the Carolinas 2025
ICML 2025
EHA 2025
1:38
Guidance on managing ocular toxicities associated with belantamab mafodotin in multiple myeloma
Meral Beksac • 17 Sep 2025
2:29
Treatment goals and preferences in RRMM: patients and physicians
Rakesh Popat • 20 Sep 2025
1:31
Managing toxicities associated with BCMA-targeting bispecific antibodies in multiple myeloma
Andrew Yee • 17 Sep 2025
2:17
Considering frailty in myeloma treatment decisions: advice for clinicians
Gareth Morgan • 18 Sep 2025
View All Videos
2:34
The IMPROVE trial: paused versus continuous BTKi therapy during vaccination in patients with CLL
Helen Parry • 17 Oct 2025
3:15
Managing patients with CLL who relapse after triplet therapy
Jacob Soumerai • 18 Sep 2025
1:29
The optimal duration of time-limited BTKi plus BCL2i combination therapies in CLL
Moritz Fürstenau • 13 Sep 2025
2:40
A real-world analysis of CNS involvement in CLL
Jacob Soumerai • 18 Sep 2025
View All Videos
1:47
Advances in MRD-guided therapy in AML & strategies being explored to eradicate MRD
Eytan Stein • 5 Sep 2025
1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
4:47
Opportunities and challenges for real-time AI decision support in transplant care
Amin Turki • 5 Sep 2025
View All Videos
4:27
The risk and management of pulmonary hypertension in patients with polycythemia vera
Joseph Scandura • 23 Aug 2025
1:20
The current role of fedratinib in the treatment of myelofibrosis
Alexander Coltoff • 23 Aug 2025
1:23
Advice for physicians managing patients with MPN-AP/BP
Anand Patel • 23 Aug 2025
1:39
The role of non-pharmacological interventions in reducing the symptom burden in MPNs
Ruben Mesa • 23 Aug 2025
View All Videos
2:51
Key unmet needs in PTCL & the need for more research in this space
Tetiana Skrypets • 20 Jun 2025
2:55
The efficacy & toxicity of radiation therapy prior to CAR T-cell therapy in R/R myeloma
Kathryn Tringale • 12 Jun 2025
2:18
The current use of radiotherapy in lymphoma & how its role has evolved in recent years
Lena Specht • 19 Jun 2025
1:42
The potential value of ultra-low-dose radiation therapy for lymphoma treatment
Lena Specht • 19 Jun 2025
View All Videos
1:34
Selecting between glofitamab and epcoritamab for elderly patients with R/R DLBCL
Swetha Thiruvengadam • 10 Jun 2025
2:49
Real-world data on the treatment of adolescents and young adults with MPNs
Claire Harrison • 23 Jun 2025
7:59
The role of therapeutic plasma exchange in managing plasma cell disorders
Danai Dima • 24 Jun 2025
2:47
Treating ALL in community settings without access to sophisticated MRD testing
Jae Park • 18 Jun 2025
View All Videos

The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).

Gold Supporter

Johnson & Johnson

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Community Focus Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals